NAV
$36.97
AUM
$20.1M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.78
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +4.32% | +10.86% | +13.02% | +17.97% | +3.39% | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 13.29% |
| 2 | JNJ | Johnson & Johnson | 8.08% |
| 3 | MRK | Merck & Co Inc | 5.95% |
| 4 | GH | Guardant Health Inc | 5.35% |
| 5 | AZN.L | AstraZeneca PLC | 4.84% |
| 6 | TMO | Thermo Fisher Scientific Inc | 4.53% |
| 7 | ARGX | argenx SE ADR | 4.07% |
| 8 | ISRG | Intuitive Surgical Inc | 3.91% |
| 9 | BSX | Boston Scientific Corp | 3.78% |
| 10 | 7741.T | Hoya Corp | 3.53% |
The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non-U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.
Inception Date: 2021-11-09